OSI Pharmaceuticals, Genentech and Roche announce data from clinical studies of Tarceva.
D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D000069347:Erlotinib Hydrochloride; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D011799:Quinazolines / Q000627:therapeutic use*
D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors